Cancer immunotherapy is a growing field nowadays. Among different molecular pathways,
PD-1/PD-L1 signaling pathway plays a significant role in the regulation of immune …

Programmed cell death-ligand 1 (PD-L1) is a glycoprotein that is expressed on the cell
surface of both hematopoietic and nonhematopoietic cells. PD-L1 play a role in the immune …

The immune checkpoint blockade (ICB) targeting on PD-1/PD-L1 has shown remarkable
promise in treating cancers. However, the low response rate and frequently observed severe …

Engagement of programmed death-ligand 1 (PD-L1) with its receptor programmed death 1
(PD-1) on T cells has been speculated to play a major role in suppressing the immune …

The development and progression of different pathologies including, cancer, are associated
with suppressed immune responses. This restrained immune activity could be associated …

Background Accumulation of immunosuppressive protein programmed death-ligand 1 (PD-
L1) has been documented in several cancers and contributes to the evasion of the host …

Cancer immunotherapy has many great achievements in recent years. One of the most
promising cancer immunotherapies is PD-1/PD-L1 pathway blockade. miRNAs (MicroRNAs) …

Abstract Background PD-L1 and PD-L2 are PD-1 ligands (PD-Ls). PD-Ls over-expression is
associated with poor prognosis in hepatocellular carcinoma (HCC). However, little is known …

Programmed death ligand-1 (PD-L1) is a critical regulator of T cell function contributing to
peripheral immune tolerance. Although it has been shown that posttranscriptional regulatory …

MicroRNAs are important regulators in multiple cellular processes and are closely related to
a variety of cancers including breast cancer (BC). Immunotherapy using different methods …